Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00006364 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : January 23, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Childhood Chronic Myelogenous Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia Relapsing Chronic Myelogenous Leukemia | Drug: omacetaxine mepesuccinate Other: pharmacological study Other: laboratory biomarker analysis | Phase 2 |
OBJECTIVES:
I. Determine the maximum tolerated dose of homoharringtonine in patients with transformed phases of chronic myelogenous leukemia (CML). (Phase I completed as of 2/11/2004.) II. Determine the toxicity profile of this drug in these patients. III. Determine the response duration in patients with chronic phase CML treated with this drug.
IV. Compare the pharmacokinetics of this drug administered as a continuous infusion vs subcutaneously in these patients.
OUTLINE: This is a pilot, dose-escalation study. (Phase I completed as of 2/11/2004.)
Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.
Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of homoharringtonine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 25-30 patients with chronic phase chronic myelogenous leukemia receives remission induction and maintenance therapy as above at the MTD. (Phase I completed as of 2/11/2004.)
Patients are followed every 3 months.
PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia |
Study Start Date : | November 1999 |
Actual Primary Completion Date : | September 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (omacetaxine mepesuccinate)
Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses. Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity. |
Drug: omacetaxine mepesuccinate
Given IV or SC
Other Names:
Other: pharmacological study Correlative studies
Other Name: pharmacological studies Other: laboratory biomarker analysis Correlative studies |
- Maximum-tolerated dose (MTD) of homoharringtonine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria (CTC) [ Time Frame: 14 days ]
- Complete hematologic remission (CHR) defined as at least 4 weeks of bone marrow (less than 5% blasts) and peripheral blood with WBC < 10 x 10^9/L and no peripheral blasts, promyelocytes, or myelocytes [ Time Frame: Up to 6 years ]Using a Bayesian approach.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis of chronic phase chronic myelogenous leukemia (CML), as defined by the following:
- Less than 15% blasts in the peripheral blood (PB) or bone marrow (BM)
- Less than 20% basophils in the PB or BM
- Platelet count > 100,000/mm^3 (unless related to therapy)
- Absence of clonal evolution*
- Philadelphia chromosome- OR BCR/ABL-positive disease by cytogenetics, fluorescence in situ hybridization, or polymerase chain reaction
-
Failed prior therapy with imatinib mesylate, as defined by any of the following:
- Failed to achieve or have lost a complete hematologic remission after 3 months of therapy
- Failed to achieve or have lost at least a minimal cytogenetic response after 6 months of therapy
- Failed to achieve or have lost a major or complete cytogenetic response after 12 months of therapy
- Unable to tolerate imatinib mesylate despite adequate dose adjustment
-
Failed no more than 2 prior treatment regimens (in addition to imatinib mesylate)
- Treatment with hydroxyurea is not considered one regimen
- Ineligible for known regimens or protocols of higher efficacy or priority
- Performance status - Zubrod 0-2
- At least 2 months
- Bilirubin no greater than 2.0 mg/dL
- Creatinine less than 2.0 mg/dL
- No New York Heart Association class III or IV heart disease
- Not pregnant or nursing
- Fertile patients must use effective contraception

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006364
United States, Texas | |
M D Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Jorge Cortes | M.D. Anderson Cancer Center |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006364 |
Other Study ID Numbers: |
NCI-2012-02360 ID 99-032 N01CM17003 ( U.S. NIH Grant/Contract ) CDR0000068237 ( Registry Identifier: PDQ (Physician Data Query) ) |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | January 23, 2013 |
Last Verified: | January 2013 |
Leukemia Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase Neoplasms by Histologic Type Neoplasms Myeloproliferative Disorders Bone Marrow Diseases |
Hematologic Diseases Homoharringtonine Antineoplastic Agents, Phytogenic Antineoplastic Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |